ozempic semaglutide weight loss without diabetes south africa Public Urged To Use Registered Products South African court blocks pharmacy

For the additional indication, the once-weekly therapy was first approved by the US FDA in August 2025, followed by a conditional approval in Canada in December

Bourgeois B, Spreitzer E, Platero-Rochart D, Paar M, Zhou Q, Usluer S, et al

Glucagon-like peptide-1 (GLP-1) improved diabetic lung fibrosis via AMPK and microRNA-27a (miR-27a) Ann

Journal Reference : Andres Acosta, Naresh Gunaratnam, Violeta Popov, Pooja Singhal, Janese Laster-Butler, Joel V

A., Killoy, K

The trial evaluated once-weekly subcutaneous semaglutide 2.4 mg versus placebo in reducing the risk of MACE (a composite endpoint comprising CV death, nonfatal MI or nonfatal stroke) in individuals with established ASCVD and overweight or obesity but without diabetes